RS62003B1 - Vezujući molekuli specifični za cd73 i njihove upotrebe - Google Patents

Vezujući molekuli specifični za cd73 i njihove upotrebe

Info

Publication number
RS62003B1
RS62003B1 RS20210770A RSP20210770A RS62003B1 RS 62003 B1 RS62003 B1 RS 62003B1 RS 20210770 A RS20210770 A RS 20210770A RS P20210770 A RSP20210770 A RS P20210770A RS 62003 B1 RS62003 B1 RS 62003B1
Authority
RS
Serbia
Prior art keywords
binding molecules
molecules specific
specific
binding
molecules
Prior art date
Application number
RS20210770A
Other languages
English (en)
Inventor
Ralph Minter
Steven Rust
Sandrine Guillard
Lutz U Jermutus
Carl Hay
Kris Sachsenmeier
Erin Sult
Qihui Huang
Peter Pavlik
Melissa Damschroder
Li Cheng
Gundo Diedrich
Jonathan Rios-Doria
Scott Hammond
Robert E Hollingsworth
Nicholas Durham
Ching Ching Leow
Mary Antonysamy
James Geoghegan
Xiaojun Lu
Kim Rosenthal
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54478033&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS62003(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of RS62003B1 publication Critical patent/RS62003B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
RS20210770A 2014-11-10 2015-11-09 Vezujući molekuli specifični za cd73 i njihove upotrebe RS62003B1 (sr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462077486P 2014-11-10 2014-11-10
US201562147329P 2015-04-14 2015-04-14
US201562188999P 2015-07-06 2015-07-06
EP15791298.1A EP3218406B1 (en) 2014-11-10 2015-11-09 Binding molecules specific for cd73 and uses thereof
PCT/EP2015/076111 WO2016075099A1 (en) 2014-11-10 2015-11-09 Binding molecules specific for cd73 and uses thereof

Publications (1)

Publication Number Publication Date
RS62003B1 true RS62003B1 (sr) 2021-07-30

Family

ID=54478033

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20210770A RS62003B1 (sr) 2014-11-10 2015-11-09 Vezujući molekuli specifični za cd73 i njihove upotrebe

Country Status (27)

Country Link
US (5) US9938356B2 (sr)
EP (2) EP3218406B1 (sr)
JP (3) JP6755866B2 (sr)
KR (1) KR20170080607A (sr)
CN (2) CN107001472B (sr)
AU (1) AU2015345202B2 (sr)
BR (1) BR112017009398A2 (sr)
CA (1) CA2967118A1 (sr)
CL (2) CL2017001154A1 (sr)
CY (1) CY1124791T1 (sr)
DK (1) DK3218406T3 (sr)
ES (1) ES2877080T3 (sr)
GB (1) GB2537445A (sr)
HR (1) HRP20210888T1 (sr)
HU (1) HUE054339T2 (sr)
IL (1) IL251891B (sr)
LT (1) LT3218406T (sr)
MX (1) MX2017005976A (sr)
MY (1) MY191423A (sr)
PL (1) PL3218406T3 (sr)
PT (1) PT3218406T (sr)
RS (1) RS62003B1 (sr)
RU (1) RU2730665C2 (sr)
SG (1) SG11201703332SA (sr)
SI (1) SI3218406T1 (sr)
TW (1) TWI710576B (sr)
WO (1) WO2016075099A1 (sr)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME03527B (me) 2013-12-12 2020-04-20 Shanghai hengrui pharmaceutical co ltd Pd-1 antitijelo, njegov fragment koji se vezuje na antigen, i njegova medicinska primjena
EP3142751B1 (en) 2014-05-13 2019-08-07 MedImmune Limited Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
DK3218406T3 (da) 2014-11-10 2021-06-21 Medimmune Ltd Bindingsmolekyler, der er specifikke for cd73, og anvendelser deraf
EP3789403A1 (en) 2014-11-11 2021-03-10 MedImmune Limited Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof
RS60998B1 (sr) 2014-11-21 2020-11-30 Bristol Myers Squibb Co Antitela koja sadrže modifikovane regione teškog lanca
PT3221363T (pt) 2014-11-21 2020-07-23 Bristol Myers Squibb Co Anticorpos contra cd73 e utilizações dos mesmos
WO2017064043A1 (en) 2015-10-12 2017-04-20 Innate Pharma Cd73 blocking agents
EP3423494A1 (en) 2016-03-04 2019-01-09 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
MA45125B1 (fr) 2016-06-02 2021-11-30 Medimmune Ltd Anticorps anti-alpha-synucléine et leurs utilisations
EP3471753A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 and il-2 cytokines
BR112019012040A2 (pt) * 2017-01-24 2019-11-12 I Mab anticorpo isolado ou fragmento do mesmo, composição, célula isolada, e, métodos para tratamento de câncer, para detecção da expressão de cd73 em uma amostra e para identificação de um paciente com câncer adequado para o tratamento com uma terapia anti-cd73.
EP3596124A1 (en) 2017-03-16 2020-01-22 Innate Pharma Compositions and methods for treating cancer
US20210107989A1 (en) * 2017-04-04 2021-04-15 Corvus Pharmaceuticals, Inc. Methods for treating cd73hi tumors
JP7090347B2 (ja) 2017-05-12 2022-06-24 ハープーン セラピューティクス，インク． メソテリン結合タンパク質
WO2018222675A1 (en) 2017-05-30 2018-12-06 The Board Of Regents Of The University Of Oklahoma Anti-doublecortin-like kinase 1 antibodies and methods of use
EP3642240A1 (en) * 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
AU2018290237A1 (en) * 2017-06-22 2020-01-16 Novartis Ag Antibody molecules to CD73 and uses thereof
JP6956254B2 (ja) * 2017-07-26 2021-11-02 チョン クン ダン ファーマシューティカル コーポレーション 血管遮断剤および免疫チェックポイント阻害剤を含む癌の予防または治療用の組成物
KR20200060471A (ko) 2017-10-06 2020-05-29 이나뜨 파르마 Cd39/cd73 축을 통한 t 세포 활성의 복원
EP3717907A1 (en) 2017-11-30 2020-10-07 Novartis AG Bcma-targeting chimeric antigen receptor, and uses thereof
JP7409669B2 (ja) * 2017-12-04 2024-01-09 ザ ボード オブ リージェンツ オブ ザ ユニバーシティ オブ オクラホマ 抗ｄｃｌｋ１抗体およびキメラ抗原受容体、ならびにこれらの組成物および使用方法
US20190292188A1 (en) 2018-02-27 2019-09-26 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
WO2019170131A1 (zh) 2018-03-07 2019-09-12 复旦大学 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途
CN110240654A (zh) * 2018-03-07 2019-09-17 复旦大学 结合cd73的抗体-药物偶联物
EP3762030A4 (en) * 2018-03-09 2022-01-05 Phanes Therapeutics, Inc. ANTI-CD73 ANTIBODIES AND USES THEREOF
KR20200130403A (ko) * 2018-03-09 2020-11-18 아게누스 인코포레이티드 항-cd73 항체 및 그의 사용 방법
BR112020020826A2 (pt) 2018-04-12 2021-01-19 Bristol-Myers Squibb Company Terapia de combinação anticâncer com anticorpo antagonista de cd73 e anticorpo antagonista do eixo pd-1/pd-l1
WO2019222677A1 (en) 2018-05-18 2019-11-21 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
EP3569618A1 (en) * 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
CA3098420A1 (en) 2018-06-01 2019-12-05 Novartis Ag Binding molecules against bcma and uses thereof
EA202092518A1 (ru) 2018-06-18 2021-08-23 Иннейт Фарма Композиции и способы лечения рака
US11034771B2 (en) 2018-07-25 2021-06-15 I-Mab Biopharma Us Limited Anti-CD73 anti-PD-L1 bispecific antibodies
CN113286817A (zh) 2018-09-25 2021-08-20 哈普恩治疗公司 Dll3结合蛋白及使用方法
BR112021007902A2 (pt) * 2018-11-12 2021-11-16 Jiangsu Hengrui Medicine Co Anticorpo anti-cd73, fragmento de ligação ao antigênio e aplicação dos mesmos
CN111434688A (zh) * 2019-01-11 2020-07-21 上海开拓者生物医药有限公司 Cd73抗体及其制备方法和应用
CN111499747B (zh) * 2019-01-11 2022-03-18 康诺亚生物医药科技（成都）有限公司 一种抗cd73单克隆抗体及其应用
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
KR20210137162A (ko) * 2019-03-12 2021-11-17 아르커스 바이오사이언시즈 인코포레이티드 종양유전자-유발 암의 치료
EP3947447A4 (en) * 2019-04-02 2023-01-11 Medimmune, LLC ANTI-CD73, ANTI-PD-L1 ANTIBODIES AND TUMOR TREATMENT CHEMOTHERAPY
CN112111008B (zh) * 2019-06-19 2024-04-30 海正生物制药有限公司 抗cd73抗体及其应用
CN112300279A (zh) * 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 针对抗cd73抗体和变体的方法和组合物
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
KR20220048026A (ko) * 2019-08-21 2022-04-19 하버 바이오메드 (상하이) 컴퍼니 리미티드 항-cd73 항체 및 이의 응용
KR20220053596A (ko) * 2019-08-30 2022-04-29 제넨테크, 인크. 치료 항체 발견을 위한 효율적인 하이브리도마 플랫폼의 개발
AU2020342778A1 (en) 2019-09-06 2022-03-31 Les Laboratoires Servier Anti-CD73 antibodies
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
EP4058150A2 (en) * 2019-11-15 2022-09-21 Genzyme Corporation Biparatopic cd73 antibodies
CR20220317A (es) * 2020-01-03 2022-09-02 Incyte Corp Anticuerpos anti-cd73 y usos de estos
US20210230294A1 (en) 2020-01-03 2021-07-29 Incyte Corporation Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy
JP2023522730A (ja) * 2020-04-22 2023-05-31 アケソ・バイオファーマ・インコーポレイテッド 抗ｃｄ７３／抗ｐｄ－１二重特異性抗体及びその使用
CA3175513A1 (en) * 2020-04-22 2021-10-28 Zhongmin Wang Anti-cd73 antibody and use thereof
US20230220104A1 (en) 2020-05-29 2023-07-13 Brightpath Biotherapeutics Co., Ltd. Anti-cd73 antibody and use thereof
WO2021247188A1 (en) 2020-06-05 2021-12-09 Bristol-Myers Squibb Company Cd73 antagonist potency assay and methods of use thereof
CN111714642A (zh) * 2020-06-18 2020-09-29 复旦大学 Cd73抗体-药物偶联物的应用
AU2021297856A1 (en) 2020-06-22 2023-02-02 Innovent Biologics (Suzhou) Co., Ltd. Anti-CD73 antibody and use thereof
AU2021306613A1 (en) 2020-07-07 2023-02-02 BioNTech SE Therapeutic RNA for HPV-positive cancer
CN114075289A (zh) * 2020-08-17 2022-02-22 中山康方生物医药有限公司 抗cd73的抗体及其用途
CN114380915B (zh) * 2020-10-19 2024-03-22 中山康方生物医药有限公司 抗cd73的抗体及其用途
JP2023546743A (ja) * 2020-10-23 2023-11-07 中山康方生物医▲藥▼有限公司 抗ｃｄ７３抗体及びその使用
EP4240491A1 (en) 2020-11-06 2023-09-13 Novartis AG Cd19 binding molecules and uses thereof
CN117126281A (zh) * 2020-11-09 2023-11-28 江苏中新医药有限公司 抗cd73单克隆抗体及其在制备肿瘤药物中的应用
TW202222840A (zh) * 2020-12-11 2022-06-16 大陸商上海華奧泰生物藥業股份有限公司 Ｃｄ７３的抗原結合蛋白及其應用
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
JP2024502005A (ja) 2020-12-29 2024-01-17 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤、ｐｄ－１／ｐｄ－ｌ１阻害剤、及び抗ｃｄ７３抗体を含む併用療法
CN113061177B (zh) * 2020-12-31 2022-07-01 浙江大学 一种cd73酶活性相关的抗原表位及针对该表位的特异性抗体的制备方法
CN113045659B (zh) * 2021-03-18 2022-03-18 上海近岸科技有限公司 抗cd73人源化抗体
GB202105110D0 (en) * 2021-04-09 2021-05-26 Cancer Research Tech Ltd Anti-CD73 antibodies
WO2022247826A1 (zh) * 2021-05-28 2022-12-01 和铂医药(上海)有限责任公司 靶向pd-l1和cd73的特异性结合蛋白
AU2022312698A1 (en) 2021-07-13 2024-01-25 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
TW202400242A (zh) * 2022-03-14 2024-01-01 大陸商上海華奧泰生物藥業股份有限公司 抗體藥物偶聯物及其應用
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
CN117304316A (zh) * 2022-06-22 2023-12-29 复旦大学 靶向cd73的纳米抗体及纳米抗体-药物偶联物、其制备方法和用途
CN116903744B (zh) * 2022-08-12 2024-03-08 南京蓬勃生物科技有限公司 抗cd73抗体或其抗原片段及其应用
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB2183661B (en) 1985-03-30 1989-06-28 Marc Ballivet Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU652539B2 (en) 1989-05-16 1994-09-01 Medical Research Council Co-expression of heteromeric receptors
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
ATE177782T1 (de) 1990-12-20 1999-04-15 Ixsys Inc Optimierung von bindenden proteinen
DE69233745D1 (de) 1991-12-02 2008-10-23 Cambridge Antibody Tech Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
ES2202310T3 (es) 1991-12-13 2004-04-01 Xoma Corporation Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6706484B1 (en) 1995-08-18 2004-03-16 Morphosys Ag Protein/(poly)peptide libraries
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
US6331431B1 (en) 1995-11-28 2001-12-18 Ixsys, Inc. Vacuum device and method for isolating periplasmic fraction from cells
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
DE60044997D1 (de) 1999-07-02 2010-11-04 Morphosys Ag Erzeugung spezifischer bindungspartner die an von genomischen dns-fragmenten oder ests kodierten (poly)peptiden binden
BR0109705A (pt) * 2000-03-31 2005-01-11 Idec Pharma Corp Uso combinado de anticorpos ou antagonistas anti-citocina e anticd20 para o tratamento de linfoma de célula b
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
NZ539395A (en) 2002-11-07 2009-01-31 Immunogen Inc Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
US7158164B2 (en) 2003-08-29 2007-01-02 Fuji Photo Film Co., Ltd. Thermal development method and apparatus
US20080187954A1 (en) 2004-03-10 2008-08-07 Lonza Ltd. Method For Producing Antibodies
US20080312425A1 (en) 2004-08-30 2008-12-18 Lonza Biologics Plc. Ion Exchange Chromatography and Purification of Antibodies
WO2008007648A1 (fr) 2006-07-10 2008-01-17 Institute For Antibodies Co., Ltd. Procédé de classification d'antigène, procédé d'identification d'antigène, procédé d'obtention d' un ensemble d'antigènes ou d'anticorps, procédés de construction d'un panel d'anticorps, anticorps et ens
EP2041574B1 (en) * 2006-07-14 2016-11-16 The Regents of The University of California Cancer biomarkers and methods of use threof
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
WO2009092014A1 (en) 2008-01-18 2009-07-23 Gagnon Peter S Enhanced purification of antibodies and antibody fragments by apatite chromatography
JP5470817B2 (ja) 2008-03-10 2014-04-16 日産自動車株式会社 電池用電極およびこれを用いた電池、並びにその製造方法
EP2374883B1 (en) * 2008-12-26 2016-08-10 Kyowa Hakko Kirin Co., Ltd. Anti-cd4 antibody
LT3279215T (lt) 2009-11-24 2020-04-10 Medimmune Limited Tiksliniai surišantys agentai prieš b7-h1
ES2609043T3 (es) 2009-11-30 2017-04-18 Janssen Biotech, Inc. Anticuerpos mutantes Fc con funciones de efecto abladas
EP2552957A4 (en) 2010-03-29 2013-11-20 Zymeworks Inc ANTIBODIES HAVING ENHANCED OR DELETED EFFECTIVE FUNCTION
US9169325B2 (en) * 2010-04-13 2015-10-27 Celldex Therapeutics, Inc. Antibodies that bind human CD27 and uses thereof
NZ603883A (en) 2010-05-27 2015-01-30 Merck Sharp & Dohme Method for preparing antibodies having improved properties
EP2537864B1 (en) 2011-06-24 2019-08-07 Laboratoire Français du Fractionnement et des Biotechnologies Fc variants with reduced effector functions
RS60828B1 (sr) 2011-10-11 2020-10-30 Viela Bio Inc Cd40l-specifične konstrukcije izvedene iz tn3 i metode za njihovu primenu
WO2014153424A1 (en) 2013-03-19 2014-09-25 La Jolla Institute For Allergy And Immunology Reducing diabetes in patients receiving hmg-coa reductase inhibitors (statins)
TWI503850B (zh) 2013-03-22 2015-10-11 Polytronics Technology Corp 過電流保護元件
AU2015329982B2 (en) 2014-10-10 2021-05-20 Innate Pharma CD73 blockade
DK3218406T3 (da) * 2014-11-10 2021-06-21 Medimmune Ltd Bindingsmolekyler, der er specifikke for cd73, og anvendelser deraf
PT3221363T (pt) 2014-11-21 2020-07-23 Bristol Myers Squibb Co Anticorpos contra cd73 e utilizações dos mesmos
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor

Also Published As

Publication number Publication date
BR112017009398A2 (pt) 2018-05-15
ES2877080T3 (es) 2021-11-16
EP3218406A1 (en) 2017-09-20
JP2020195394A (ja) 2020-12-10
MY191423A (en) 2022-06-27
LT3218406T (lt) 2021-06-25
AU2015345202B2 (en) 2021-05-13
US11525012B2 (en) 2022-12-13
US10556968B2 (en) 2020-02-11
RU2017117596A3 (sr) 2019-06-17
CL2020003409A1 (es) 2021-07-02
US20180194858A1 (en) 2018-07-12
MX2017005976A (es) 2017-06-29
CN112778418A (zh) 2021-05-11
JP2022115962A (ja) 2022-08-09
CN107001472B (zh) 2020-12-11
EP3218406B1 (en) 2021-03-24
PT3218406T (pt) 2021-06-17
CY1124791T1 (el) 2022-11-25
GB201519761D0 (en) 2015-12-23
US20160194407A1 (en) 2016-07-07
US10287362B2 (en) 2019-05-14
CA2967118A1 (en) 2016-05-19
DK3218406T3 (da) 2021-06-21
RU2017117596A (ru) 2018-12-17
SG11201703332SA (en) 2017-05-30
KR20170080607A (ko) 2017-07-10
CL2017001154A1 (es) 2018-01-12
AU2015345202A1 (en) 2017-05-18
HUE054339T2 (hu) 2021-08-30
TWI710576B (zh) 2020-11-21
CN107001472A (zh) 2017-08-01
JP6755866B2 (ja) 2020-09-16
WO2016075099A1 (en) 2016-05-19
US20190292274A1 (en) 2019-09-26
JP7069261B2 (ja) 2022-05-17
US20230340152A1 (en) 2023-10-26
IL251891A0 (en) 2017-06-29
EP3901176A1 (en) 2021-10-27
US20200079877A1 (en) 2020-03-12
JP2018501197A (ja) 2018-01-18
SI3218406T1 (sl) 2021-08-31
US9938356B2 (en) 2018-04-10
RU2730665C2 (ru) 2020-08-24
TW201632555A (zh) 2016-09-16
IL251891B (en) 2021-03-25
HRP20210888T1 (hr) 2021-07-23
PL3218406T3 (pl) 2021-10-04
GB2537445A (en) 2016-10-19

Similar Documents

Publication Publication Date Title
IL251891B (en) Specific binding molecules for cd73 and their uses
IL283965A (en) Antibodies against cd73 and their uses
ZA201702173B (en) Sorbent for binding metal and production thereof
GB201612520D0 (en) Binding molecules
IL273641B (en) Specific binding molecules for il-21 and uses thereof
IL250796A0 (en) lox1-specific binding proteins and their uses
HK1258317A1 (zh) 對asct2具有特異性的結合分子及其用途
EP3180027A4 (en) Rspo1 binding agents and uses thereof
GB201508729D0 (en) Binding molecules